GeoVax Labs
GOVXNASDAQUSD
- — Source valuation snapshot. Not a live recalculation.
- — Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- — Diluted earnings per share from the latest filed annual.
- $2.68 Prior regular-session close from the quote source.
- $1.85–$3.00 Regular-session low and high so far today.
- 438.8K Regular-session shares traded · Nov 11, 1:29 PM ET.
- Nov 12 projected Projected for 2026-11-12 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $0.11–$13.00 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own GOVX if GeoVax is not a normal operating-business thesis; it is a financing- and milestone-dependent biotech option whose value depends on converting pharmaceutical R&D into externally funded validation before cash and dilution erase the upside.
GOVX price history
Loading recent earnings…
INVESTMENT THESIS
What must happen next
GeoVax’s R&D platform needs recurring external validation from contracts, grants, or partners because it does not yet have a commercial product engine to fund itself.HoldingMateriality: High
GAAP annual revenue was $2.49 million in FY2025, showing some external contract or customer funding existed. If external demand for the science is real, revenue and funding can extend the option value; if it is one-off, shareholders are left funding losses through dilution.
Watch: Government or institutional funders redirect infectious-disease or vaccine funding toward larger platforms with later-stage data.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue was $2.49 million in FY2025, showing some external contract or customer funding existed.
Open source ↗The platform’s upside is constrained by access to capital, because ongoing R&D burn is far larger than current revenue or cash resources.WeakeningMateriality: High
GAAP annual operating cash flow was negative $21.47 million in FY2025. Even good science can be a poor stock if the next milestones require rescue financing at distressed prices.
Watch: The equity market closes to microcap biotech financings after a Nasdaq compliance or liquidity shock.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow was negative $21.47 million in FY2025.
Open source ↗Management must keep development spending aligned with funded programs rather than broaden self-funded trials, or the remaining pipeline option will be consumed by operating losses.HoldingMateriality: Medium
GAAP annual operating loss improved to $21.64 million in FY2025 from $25.14 million in FY2024. Disciplined spending buys time for a value-creating milestone; undisciplined burn forces dilution before the science can mature.
Watch: GeoVax initiates or expands costly clinical trials without a partner, grant, or dedicated financing.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating loss improved to $21.64 million in FY2025 from $25.14 million in FY2024.
Open source ↗A modest liability burden gives common shareholders some residual option value, but that advantage disappears if survival financing comes through toxic debt or highly dilutive securities.StrengtheningMateriality: Medium
Total liabilities were $2.52 million at FY2025 year-end versus $3.11 million at FY2024 year-end. For a microcap biotech, capital structure can determine whether a successful milestone benefits current holders or mostly new financiers.
Watch: GeoVax issues convertible debt or preferred securities with reset features, warrants, or deep discounts.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Total liabilities were $2.52 million at FY2025 year-end versus $3.11 million at FY2024 year-end.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
GeoVax’s R&D platform needs recurring external validation from contracts, grants, or partners because it does not yet have a commercial product engine to fund itself. If external demand for the science is real, revenue and funding can extend the option value; if it is one-off, shareholders are left funding losses through dilution.
The platform’s upside is constrained by access to capital, because ongoing R&D burn is far larger than current revenue or cash resources. Even good science can be a poor stock if the next milestones require rescue financing at distressed prices.
Management must keep development spending aligned with funded programs rather than broaden self-funded trials, or the remaining pipeline option will be consumed by operating losses. Disciplined spending buys time for a value-creating milestone; undisciplined burn forces dilution before the science can mature.
A modest liability burden gives common shareholders some residual option value, but that advantage disappears if survival financing comes through toxic debt or highly dilutive securities. For a microcap biotech, capital structure can determine whether a successful milestone benefits current holders or mostly new financiers.
All standing thesis claims
Original report summary
GeoVax is not a normal operating-business thesis; it is a financing- and milestone-dependent biotech option whose value depends on converting pharmaceutical R&D into externally funded validation before cash and dilution erase the upside.
BULL CASE / BEAR CASE
Bull case and bear case for GeoVax Labs
Where the evidence on GeoVax Labs disagrees: Mixed on the latest evidence (Oct 15, 2026). Of its 4 thesis points, 1 strengthening, 2 holding and 1 weakening.
Bull case: what the evidence supports
GeoVax’s R&D platform needs recurring external validation from contracts, grants, or partners because it does not yet have a commercial product engine to fund itself.
Management must keep development spending aligned with funded programs rather than broaden self-funded trials, or the remaining pipeline option will be consumed by operating losses.
A modest liability burden gives common shareholders some residual option value, but that advantage disappears if survival financing comes through toxic debt or highly dilutive securities.
Bear case: what the evidence questions
The platform’s upside is constrained by access to capital, because ongoing R&D burn is far larger than current revenue or cash resources.
Thesis-Break Engine
What has broken in GeoVax Labs’s thesis
Each break OptimistFi flagged on GeoVax Labs, dated — with what has historically followed the same kind of break across the market, not a forecast for GeoVax Labs.
- CEO / officer changecondition set before this filing
Across all companies, this kind of break has happened 16,849 times before. Those stocks trailed comparable companies by a median of 2% over the next six months, and 38% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MIXEDOther material event.
GeoVax Labs filed an SEC 8-K on 2026-09-10: Other material event. It is a dated development that tests the current thesis.
- MIXEDDelisting notice or listing-rule failure.
GeoVax Labs filed an SEC 8-K on 2026-08-28: Delisting notice or listing-rule failure. It is a dated development that tests the current thesis.
- MIXEDEntered a material definitive agreement.
GeoVax Labs filed an SEC 8-K on 2026-08-28: Entered a material definitive agreement. It is a dated development that tests the current thesis.
RISKS / FALSIFIERS
What could break the thesis
- Government or institutional funders redirect infectious-disease or vaccine funding toward larger platforms with later-stage data.
- The equity market closes to microcap biotech financings after a Nasdaq compliance or liquidity shock.
- GeoVax initiates or expands costly clinical trials without a partner, grant, or dedicated financing.
- GeoVax issues convertible debt or preferred securities with reset features, warrants, or deep discounts.
GOVX news
Loading headlines…
FINANCIAL STATEMENTS
GOVX income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
GOVX: quick answers
- When does GeoVax Labs (GOVX) report earnings next?
- GeoVax Labs's next results are projected for November 12, 2026, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on July 27, 2026. Earnings calendar
- What is GOVX's short interest?
- As of October 30, 2026, 175,903 GOVX shares were sold short, down 34.9% from the count before. At the stock's average daily volume that is 1.0 day to cover. FINRA publishes the count twice a month. GOVX short interest history